MSH2 and neoplasm: Of note, the tumors resulting from MYC-sgp53-sgMsh2 EPO harbored genetic alterations of the Msh2 locus and lacked MSH2 expression in the tumor (Fig. 3b and Extended Data Fig. 6a), so despite the extended survival, Msh2 disruption seemed to confer a selective advantage during tumorigenesis.